Beam Therapeutics Inc (BEAM)

$26.04 0.53 (2.08%)

16:00 EDT BEAM Stock Quote Delayed 30 Minutes

3 Gene Editing Stocks with Potential to Transform Medicine

By Ian Cooper, InvestorPlace Contributor Aug 9, 2024

Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.

BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024

Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40

3 Gene Editing Stocks Shaping the Future of Medicine

Volume:

Previous Close -

Market Cap 2.06B

PE Ratio -15.98

EPS -1.63

Volume (Avg. Vol.) 633,263

Day's Range $25.87 - $26.67

52-Week Range $16.95 - $49.50

Dividend & Yield N/A (N/A)

BEAM Stock Predictions, Articles, and Beam Therapeutics Inc News

3 Stocks With the Potential to 10X Your Money

By Stavros Tousios, InvestorPlace Contributor Jul 9, 2024

These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost.

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

By Joel Lim, InvestorPlace Contributor Jul 4, 2024

Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.

3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030

By Omor Ibne Ehsan Jul 3, 2024

These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet.

You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.

By Viktor Zarev, InvestorPlace Contributor Jun 27, 2024

The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects.

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine

By Jeremy Flint, InvestorPlace Contributor May 9, 2024

These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.

BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024

By InvestorPlace Earnings May 7, 2024

BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

3 Biotech Stocks to Buy on the Dip: February 2024

By Chris Markoch, InvestorPlace Contributor Feb 7, 2024

Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

By Jeremy Flint, InvestorPlace Contributor Jan 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

3 Stocks to Buy in the Booming Field of Gene Editing

By Chris Markoch, InvestorPlace Contributor Jan 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

The 3 Best Gene Editing Stocks on the Frontier of Medicine

By Ian Cooper, InvestorPlace Contributor Nov 20, 2023

Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.

Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On

By Yiannis Zourmpanos, InvestorPlace Contributor Nov 1, 2023

Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.

7 Best Cathie Wood Stocks for Your May 2023 Buy List

By Alex Sirois, InvestorPlace Contributor May 2, 2023

This year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent.

The 3 Most Promising Gene Editing Stocks to Buy in 2023

By John Blankenhorn, InvestorPlace Contributor Apr 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

3 Stocks to Watch in April: Is it Time to Buy?

By Josh Enomoto, InvestorPlace Contributor Apr 18, 2023

With several fundamental factors pushing against the equities sector, these stocks to watch in particular draw significant intrigue.

7 Top Growth Stocks to Buy for the Next Decade

By Alex Sirois, InvestorPlace Contributor Apr 18, 2023

These Growth Stocks to Buy Don't Require a 10-year Horizon But Should be More Valuable Then

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

By Josh Enomoto, InvestorPlace Contributor Mar 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

By John Blankenhorn, InvestorPlace Contributor Mar 6, 2023

CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on.

The Top 7 Growth Stocks in Biotech

By Alex Sirois, InvestorPlace Contributor Mar 3, 2023

The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term.

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois, InvestorPlace Contributor Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

7 ‘Next Big Things’ for Investors to Buy for 2023

By Chris Lau, InvestorPlace Contributor Dec 13, 2022

The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.

Beam Therapeutics Inc (BEAM)

3 Gene Editing Stocks with Potential to Transform Medicine

BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024

Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40

3 Gene Editing Stocks Shaping the Future of Medicine

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Beam Therapeutics Inc (BEAM)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

BEAM Stock Predictions, Articles, and Beam Therapeutics Inc News

Subscriber Sign in